Drugs / VIC-1911
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07350057 | Mar → Dec 2026 expected | graft versus host disease | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05374538 | Nov 2022 → Aug 2023 | non-small cell lung carcinoma | Vitrac Therapeutics, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT05489731 | Sep 2022 → Feb 2024 | non-small cell lung carcinoma | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05120570 | Mar 2022 → Sep 2024 | acute leukemia, lymphoma, myelodysplastic syndrome, myeloproliferative neoplasm | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06519721 | Aug 2024 → Dec 2025 overdue | hepatocellular carcinoma | RenJi Hospital | Active not recruiting | No outcome recorded |
| — | NCT05718882 | Aug 2023 → Apr 2024 | hepatocellular carcinoma, refractory malignant neoplasm | RenJi Hospital | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIC-1911 | “VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral.” NCT05718882 ↗5“VIC-1911, a selective oral Aurora kinase A (AURKA) inhibitor” PMID 41592279 ↗ Apr 2026 |
| Action | Inhibit | “VIC-1911, a selective oral Aurora kinase A (AURKA) inhibitor” PMID 41592279 ↗ Apr 2026 |
| Route | Oral | “VIC-1911, a selective oral Aurora kinase A (AURKA) inhibitor” PMID 41592279 ↗ Apr 2026 |
| Target | AURKA | “VIC-1911, a selective oral Aurora kinase A (AURKA) inhibitor” PMID 41592279 ↗ Apr 2026 |